|
 |
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print February 16, 2004
J. Lipid Res., doi:10.1194/jlr.M300520-JLR200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CEO, Pacific Health Research Institute, Honolulu, HI 96813
Corresponding Author: jdcurb{at}phrihawaii.org
Objective: High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with the incidence of coronary heart disease (CHD) in middle-aged individuals. In the elderly, the association is less clear. Genetic factors, including variations in the cholesteryl ester transfer protein (CETP) gene, play a role in determining HDL-C levels. Controversy remains about whether CETP deficiency and the resultant rise in HDL-C are anti-atherogenic or whether CETP has the opposite effect due to its role in reverse cholesterol transport. Methods and Results: In a 7-year follow-up of 2340 men aged 71-93 in the Honolulu Heart Program, the age-adjusted CHD incidence rates were significantly lower in men with high versus low HDL-C levels. After adjustment for age, hypertension, smoking and total cholesterol, the relative risk of CHD for those with HDL-C levels =60 mg/dl compared to those with HDL-C levels <40 mg/dl was 0.6. Men with a CETP mutation had the lowest rates of CHD, although this was not statistically significant. Conclusion: These data indicate that HDL-C remains an important risk factor for CHD in the elderly. Whether a CETP mutation offers additional protection against CHD warrants further investigation.
Revised on February 6, 2004
Accepted on February 9, 2004
A prospective study of HDL cholesterol and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. von Eckardstein Mulling over the odds of CETP inhibition Eur. Heart J., February 2, 2010; 31(4): 390 - 393. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., January 2, 2010; 31(2): 149 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan, M. J. Pencina, S. J. Robins, J. P. Zachariah, G. Kaur, R. B. D'Agostino, and J. M. Ordovas Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community Circulation, December 15, 2009; 120(24): 2414 - 2420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah The Yin and Yang of Cholesteryl Ester Transfer Protein in Cardiovascular Disease Circulation, December 15, 2009; 120(24): 2408 - 2410. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Masson, X.-C. Jiang, L. Lagrost, and A. R. Tall The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis J. Lipid Res., April 1, 2009; 50(Supplement): S201 - S206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ridker, G. Pare, A. N. Parker, R. Y.L. Zee, J. P. Miletich, and D. I. Chasman Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study Circ Cardiovasc Genet, February 1, 2009; 2(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Field, K. Watt, and S. N. Mathur Origins of intestinal ABCA1-mediated HDL-cholesterol J. Lipid Res., December 1, 2008; 49(12): 2605 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Regieli, J. W. Jukema, D. E. Grobbee, J. J.P. Kastelein, J. A. Kuivenhoven, A. H. Zwinderman, Y. van der Graaf, M. L. Bots, and P. A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur. Heart J., November 2, 2008; 29(22): 2792 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Koropatnick, J. Kimbell, R. Chen, J. S. Grove, T. A. Donlon, K. H. Masaki, B. L. Rodriguez, B. J. Willcox, K. Yano, and J. D. Curb A Prospective Study of High-Density Lipoprotein Cholesterol, Cholesteryl Ester Transfer Protein Gene Variants, and Healthy Aging in Very Old Japanese-American Men J Gerontol A Biol Sci Med Sci, November 1, 2008; 63(11): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk JAMA, June 18, 2008; 299(23): 2777 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Lackner, L. J. Cohn, R. P. Dullaart, A. C. M. Kobold, A. van Tol, P. Barter, C. L. Shear, J. H. Revkin, and D. J. Rader Torcetrapib and Coronary Events N. Engl. J. Med., April 24, 2008; 358(17): 1862 - 1864. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zeller, D. Masson, M. Farnier, L. Lorgis, V. Deckert, J.-P. Pais de Barros, C. Desrumaux, P. Sicard, J. Grober, D. Blache, et al. High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1948 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter, A. M. Gotto, J. C. LaRosa, J. Maroni, M. Szarek, S. M. Grundy, J. J.P. Kastelein, V. Bittner, J.-C. Fruchart, and the Treating to New Targets Investigators HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events N. Engl. J. Med., September 27, 2007; 357(13): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Schechter Longevity and Cardiovascular Disease: Context and Overview Arch Intern Med, March 12, 2007; 167(5): 428 - 429. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde High-density genotyping and functional SNP localization in the CETP gene J. Lipid Res., February 1, 2007; 48(2): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tall, L. Yvan-Charvet, and N. Wang The Failure of Torcetrapib: Was it the Molecule or the Mechanism? Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 257 - 260. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease Eur. Heart J., January 1, 2007; 28(1): 5 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Barzilai, G. Atzmon, C. A. Derby, J. M. Bauman, and R. B. Lipton A genotype of exceptional longevity is associated with preservation of cognitive function Neurology, December 26, 2006; 67(12): 2170 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Florvall, S. Basu, and A. Larsson Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men J Gerontol A Biol Sci Med Sci, December 1, 2006; 61(12): 1262 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Willcox, D. C. Willcox, Q. He, J. D. Curb, and M. Suzuki Siblings of Okinawan Centenarians Share Lifelong Mortality Advantages J Gerontol A Biol Sci Med Sci, April 1, 2006; 61(4): 345 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Packard, I. Ford, M. Robertson, J. Shepherd, G. J. Blauw, M. B. Murphy, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, A. Gaw, et al. Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation, November 15, 2005; 112(20): 3058 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dumont, T. Gautier, J.-P. P. de Barros, H. Laplanche, D. Blache, P. Ducoroy, J. Fruchart, J.-C. Fruchart, P. Gambert, D. Masson, et al. Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI J. Biol. Chem., November 11, 2005; 280(45): 38108 - 38116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Wolfe and D. J. Rader Cholesteryl Ester Transfer Protein and Coronary Artery Disease: An Observation With Therapeutic Implications Circulation, September 14, 2004; 110(11): 1338 - 1340. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt, J.-A. Kuivenhoven, N. J. Wareham, R. J.G. Peters, J. W. Jukema, R. Luben, S. A. Bingham, N. E. Day, J. J.P. Kastelein, and K.-T. Khaw Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study Circulation, September 14, 2004; 110(11): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |